PPIDT00319
Drug Information
| Name | Avelumab |
|---|---|
| Sequence | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB11945 |
| Type | biotech |
| Indication | Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC).[L48126, L48171] In the US, it is also used in patients 12 years and older.[L48121] It is also indicated as the maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma (UC), which has not progressed with first-line platinum-containing chemotherapy.[L40373, L48126, L48171] In the US, avelumab is also indicated to treat locally advanced or metastatic UC with disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.[L40373] Avelumab is indicated, in combination with [axitinib], for the first-line treatment of advanced renal cell carcinoma (RCC).[L40373] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
20 mg/mL
|
| Injection, solution, concentrate | Intravenous |
20 mg/1mL
|
| Injection, solution, concentrate | Intravenous; Parenteral |
20 MG/ML
|
| Solution | Intravenous |
20 mg / mL
|
| Solution | Intravenous |
200 mg
|
| Injection, solution | Intravenous |
200 mg/10ml
|
| Injection, solution, concentrate | Intravenous |
200 mg/10ml
|
| Solution | Intravenous |
2000000 mg
|